I

n a widely anticipated move, a pharmaceutical industry trade group has filed a lawsuit seeking to stifle a new California law that requires drug makers to explain and justify price hikes.

The law has been hailed by supporters as a key attempt to provide transparency into opaque pricing practices amid growing public outrage over the cost of medicines. Not only is the law one of the more comprehensive efforts to address the issue, but California is seen as a bellwether for the rest of the nation and drug makers fear other states will attempt to adopt similar measures.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy